Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 5. Treatment with continuous low-dose doxorubicin plus MSC.sFlt1 leaded to tumor remission and was safe in vivo. (A) Animals bearing HepG2 xenografts began treatments when tumor diameters reached 5 mm as described in "Materials and Methods." Arrows: days on which treatment was administered. Results are given as mean tumor volume of 7 mice /group. *p < 0.05, vs MSC.sFlt1 plus continuous low-dose doxorubicin group. (B) HE staining was to examine general tumor tissue morphology from saline group, continuous low-dose doxorubicin group, MSC.sFlt1 group and MSC.sFlt1 plus continuous low-dose doxorubicin group. Magnification, 200×.